000839228 000__ 05343cam\a2200589Ii\4500
000839228 001__ 839228
000839228 005__ 20230306144718.0
000839228 006__ m\\\\\o\\d\\\\\\\\
000839228 007__ cr\un\nnnunnun
000839228 008__ 180514s2018\\\\sz\\\\\\ob\\\\001\0\eng\d
000839228 019__ $$a1035749408$$a1040612587
000839228 020__ $$a9783319668338$$q(electronic book)
000839228 020__ $$a3319668331$$q(electronic book)
000839228 020__ $$z9783319668321
000839228 020__ $$z3319668323
000839228 0247_ $$a10.1007/978-3-319-66833-8$$2doi
000839228 035__ $$aSP(OCoLC)on1035556492
000839228 035__ $$aSP(OCoLC)1035556492$$z(OCoLC)1035749408$$z(OCoLC)1040612587
000839228 040__ $$aN$T$$beng$$erda$$epn$$cN$T$$dN$T$$dEBLCP$$dYDX$$dAZU$$dUAB$$dOCLCF$$dOCLCQ
000839228 049__ $$aISEA
000839228 050_4 $$aHD9665.5
000839228 08204 $$a338.476151
000839228 1001_ $$aGassmann, Oliver,$$d1967-$$eauthor.
000839228 24510 $$aLeading Pharmaceutical Innovation :$$bHow to Win the Life Science Race /$$cOliver Gassmann, Alexander Schuhmacher, Max von Zedtwitz, Gerrit Reepmeyer.
000839228 250__ $$aThird edition.
000839228 264_1 $$aCham, Switzerland :$$bSpringer,$$c[2018]
000839228 300__ $$a1 online resource.
000839228 336__ $$atext$$btxt$$2rdacontent
000839228 337__ $$acomputer$$bc$$2rdamedia
000839228 338__ $$aonline resource$$bcr$$2rdacarrier
000839228 347__ $$atext file$$bPDF$$2rda
000839228 504__ $$aIncludes bibliographical references and index.
000839228 5050_ $$aIntro; Preface; Testimonials; Contents; About the Authors; 1: Innovation: Key to Success in the Pharmaceutical Industry; 1.1 The Productivity Paradox; 1.2 The Blockbuster Imperative; Entering the Market Quickly; 1.3 High Risks in Drug Development; Differentiation via Clinical Profiles; 1.4 Outlook; 2: The Industry Challenge: Who Would Want to Be in This Business?; 2.1 A Highly Complex Industry; Industry Classification and Background; Extensive Product Groups; 2.2 Five Forces Analysis of the Drug Industry; Force 1: Bargaining Power of Suppliers; Force 2: Bargaining Power of Buyers
000839228 5058_ $$aForce 3: Risk of Entry from Potential CompetitorsForce 4: Threat of Substitute Products; Force 5: Rivalry Among Established Companies; Force 6: The Regulators; RandD Regulations; Price Regulations and National Healthcare Systems; Intellectual Property Rights; 2.3 Pressure on the Traditional Pharma Business Model; Continued Rise of Generics/Branded Generics Products; Relevance of Specialty Pharma Drugs; Pressure on Portfolio Optimization; Increasingly Competitive Marketing Efforts; Legal Challenges; 2.4 Growth Drivers for the Years to Come; 2.5 Seeking Salvation in MandA and Diversification
000839228 5058_ $$aCase in Point: Mergermania Around Actavis/AllerganMotivations for Pharma MandA; Growth Through Diversification; 2.6 Conclusions; 3: The Science and Technology Challenge: How to Find New Drugs; 3.1 Rise of the Biotechnology Industry: Boosting Innovation; 3.2 The Challenge of Target Discovery; 3.3 High-Throughput Screening: Fail Earlier, Succeed Sooner; Combinatorial Chemistry: Cut Experimental Cycle Times; Hit and Lead Generation Technologies Beyond HTS; 3.4 The Bioinformatics and eHealthcare Revolution; ``Big Data`` and Its Relevance for Pharmaceutical RandD
000839228 5058_ $$a3.5 Proteomics and the `-omics ́World3.6 Pharmacogenetics and Pharmacogenomics; 3.7 Computer-Based Drug Discovery; 3.8 Conclusions; 4: The Pipeline Challenge: How to Organize Innovation; 4.1 The Relevance of Pipeline Management; Complexity and Phases of the RandD Process; 4.2 Phases and Checkpoints in the Pharma RandD Process; Case-in-Point: Risk Assessment of a Drug Candidate: Pantoprazole; Stage-Gate and Portfolio Management; 4.3 Portfolio Analysis; Application of a Financial Evaluation of a Project: The Case of Biotech; 4.4 Portfolio Management
000839228 5058_ $$aPortfolio Decision-Making at Merck Serono S.A.4.5 Conclusions; 5: The Make-or-Buy Challenge: How to In- and Outsource Innovation; 5.1 The Disaggregation of the Pharma Value Chain; 5.2 Outsourcing of Pharmaceutical RandD; Outsourcing Strategy: Captive Offshoring at ALTANA Pharma; AJ Biologics: Successful Partnering of a Vaccine Start-Up; Contract Research Organizations (CROs); Strategic CRO Partners of Pfizer; Managing Outsourcing Activities at Solvias; 5.3 Strategic Research Partnerships; 5.4 In-licensing: Enhancing the Innovation Pipeline; 5.5 Co-development: Benefiting from Joint Resources
000839228 506__ $$aAccess limited to authorized users.
000839228 520__ $$aThis book focuses on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of internationalisation, such as outside-in innovation in the early phases of R&D.
000839228 588__ $$aOnline resource; title from PDF title page (viewed  May 17, 2018).
000839228 650_0 $$aPharmaceutical industry$$xTechnological innovations.
000839228 650_0 $$aPharmaceutical industry$$xTechnological innovations$$vCase studies.
000839228 650_0 $$aDrugs$$xResearch$$xManagement.
000839228 650_0 $$aDrugs$$xResearch$$xManagement$$vCase studies.
000839228 7001_ $$aSchuhmacher, Alexander,$$eauthor.
000839228 7001_ $$aZedtwitz, Maximilian von,$$d1969-$$eauthor.
000839228 7001_ $$aReepmeyer, Gerrit,$$d1976-$$eauthor.
000839228 77608 $$iPrint version: $$z3319668323$$z9783319668321$$w(OCoLC)994792646
000839228 852__ $$bebk
000839228 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-3-319-66833-8$$zOnline Access$$91397441.1
000839228 909CO $$ooai:library.usi.edu:839228$$pGLOBAL_SET
000839228 980__ $$aEBOOK
000839228 980__ $$aBIB
000839228 982__ $$aEbook
000839228 983__ $$aOnline
000839228 994__ $$a92$$bISE